HCV infection may therefore promote the development of PAH by activating the STAT3 and COX-2/PGE2 pathways, leading to increased PASMC proliferation, endothelial dysfunction, and chronic inflammation. The gene discussed is STAT3; the disease is pulmonary arterial hypertension.